Exelon |
rivastigmine tartrate |
Clinical Trial: Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
This study is currently recruiting patients.
|
Purpose
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: rivastigmine tartrate (Exelon) | Phase IV |
MedlinePlus related topics: Alzheimer's Caregivers; Alzheimer's Disease
Genetics Home Reference related topics: Alzheimer disease
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Pharmacodynamics Study
Study start: October 2003
Eligibility
Ages Eligible for Study: 50 Years - 85 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Clinical diagnosis of mild to moderate Alzheimer's disease
- Must be able to swallow capsule/tablet
- Must have a caregiver who is available to attend all study visits
Exclusion Criteria:
- Digestive problems related to peptic ulcer
- Experienced a heart attack or stroke in the last 6 months
- Serious/unstable asthma or severe pulmonary (lung) disease
- On current treatment with a blood thinner
Location and Contact Information
New Jersey
Novartis Pharmaceuticals, East Hanover, New Jersey, 07936, United States; Recruiting
More Information
Click here for information about study sites in your area
Record last reviewed: February 2005
Last Updated: March 1, 2005
Record first received: February 28, 2005
ClinicalTrials.gov Identifier: NCT00104442
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Exelon Consumer Information (U.S. Food and Drug Administration)

Not Signed In -

